Scorpius Holdings Announces Removal of NYSE American Trading Suspension; Expected to Resume Normal Trading on August 2, 2024
Scorpius Holdings (NYSE American: SCPX), a contract development and manufacturing organization (CDMO), has announced the removal of its NYSE American trading suspension. The company's common stock is expected to resume normal trading on August 2, 2024, under the symbol 'SCPX'.
The NYSE Regulation staff has withdrawn its delisting determination after confirming that Scorpius' stock is now trading above the low selling price threshold defined in Section 1003(f)(v) of the NYSE American Company Guide. This development allows Scorpius to maintain its listing on the NYSE American exchange.
Scorpius Holdings specializes in rapidly advancing biologic and cell therapy programs, offering analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas.
Scorpius Holdings (NYSE American: SCPX), un'organizzazione di sviluppo e produzione sotto contratto (CDMO), ha annunciato la revoca della sospensione della negoziazione sulla NYSE American. Si prevede che le azioni ordinarie dell'azienda riprenderanno la negoziazione normale il 2 agosto 2024, sotto il simbolo 'SCPX'.
Il personale della regolamentazione della NYSE ha ritirato la sua determinazione di delisting dopo aver confermato che le azioni di Scorpius stanno ora negoziando sopra la soglia di prezzo di vendita minima definita nella Sezione 1003(f)(v) della Guida alle aziende della NYSE American. Questo sviluppo consente a Scorpius di mantenere la sua quotazione sul mercato della NYSE American.
Scorpius Holdings si specializza nel rapido avanzamento di programmi biologici e di terapia cellulare, offrendo servizi di analisi, sviluppo di processi e produzione a aziende farmaceutiche e biotecnologiche presso le sue strutture a San Antonio, Texas.
Scorpius Holdings (NYSE American: SCPX), una organización de desarrollo y fabricación por contrato (CDMO), ha anunciado la eliminación de su suspensión de negociación en la NYSE American. Se espera que las acciones comunes de la compañía reanuden la negociación normal el 2 de agosto de 2024, bajo el símbolo 'SCPX'.
El personal de regulación de la NYSE ha retirado su determinación de deslistado después de confirmar que las acciones de Scorpius ahora están negociando por encima del umbral de precio de venta mínimo definido en la Sección 1003(f)(v) de la Guía de Empresas de NYSE American. Este desarrollo permite a Scorpius mantener su listado en la bolsa NYSE American.
Scorpius Holdings se especializa en avanzar rápidamente en programas biológicos y de terapia celular, ofreciendo servicios de pruebas analíticas, desarrollo de procesos y fabricación a empresas farmacéuticas y biotecnológicas en sus instalaciones en San Antonio, Texas.
Scorpius Holdings (NYSE American: SCPX), 계약 개발 및 제조 조직(CDMO)은 NYSE American 거래 중단의 제거를 발표했습니다. 이 회사의 일반 주식은 2024년 8월 2일에 'SCPX' 기호로 정상 거래를 재개할 것으로 예상됩니다.
NYSE 규제 직원은 Scorpius의 주식이 현재 NYSE American 회사 가이드의 섹션 1003(f)(v)에서 정의된 최저 판매 가격 기준 이상에서 거래되고 있음을 확인한 후 상장 폐지 결정을 철회했습니다. 이 발전으로 Scorpius는 NYSE American 거래소에서 상장을 유지할 수 있습니다.
Scorpius Holdings는 생물학 및 세포 치료 프로그램을 신속하게 발전시키는 데 전문화되어 있으며, 텍사스주 샌안토니오에 위치한 시설에서 제약 및 생명공학 회사에 분석 테스트, 프로세스 개발 및 제조 서비스를 제공합니다.
Scorpius Holdings (NYSE American: SCPX), une organisation de développement et de fabrication sous contrat (CDMO), a annoncé la levée de la suspension de sa négociation sur NYSE American. Les actions ordinaires de la société devraient reprendre une négociation normale le 2 août 2024, sous le symbole 'SCPX'.
Le personnel de régulation de la NYSE a retiré sa détermination de radiation après avoir confirmé que les actions de Scorpius se négocient désormais au-dessus du seuil de prix de vente minimum défini dans la section 1003(f)(v) du Guide des entreprises de NYSE American. Ce développement permet à Scorpius de conserver son inscription sur la bourse NYSE American.
Scorpius Holdings se spécialise dans l'avancement rapide des programmes biologiques et de thérapie cellulaire, en offrant des services de tests analytiques, de développement de processus et de fabrication aux entreprises pharmaceutiques et biotechnologiques dans ses installations à San Antonio, Texas.
Scorpius Holdings (NYSE American: SCPX), eine Organisation für Entwicklungs- und Produktionsverträge (CDMO), hat die Aufhebung ihrer Handelsaussetzung an der NYSE American bekannt gegeben. Der Handel mit den Stammaktien des Unternehmens soll am 2. August 2024 unter dem Symbol 'SCPX' wieder aufgenommen werden.
Die Mitarbeiter der NYSE-Regulierung haben ihre Entscheidung zur Delistung zurückgezogen, nachdem sie bestätigt hatten, dass die Aktien von Scorpius nun über der in Abschnitt 1003(f)(v) des NYSE American Company Guide definierten niedrigen VerkaufsPreisgrenze handeln. Diese Entwicklung ermöglicht es Scorpius, seine Listung an der NYSE American zu behalten.
Scorpius Holdings spezialisiert sich auf die schnelle Weiterentwicklung von biologischen und Zelltherapieprogrammen und bietet analytische Tests, Prozessentwicklung und Fertigungsdienstleistungen für Pharma- und Biotechunternehmen an seinen Einrichtungen in San Antonio, Texas, an.
- Removal of NYSE American trading suspension
- Expected resumption of normal trading on August 2, 2024
- Withdrawal of delisting determination by NYSE Regulation staff
- Stock price recovery above the low selling price threshold
- None.
Insights
The removal of NYSE American trading suspension for Scorpius Holdings (NYSE American: SCPX) is a significant development that warrants investor attention. This news indicates a positive shift in the company's market position, as it has successfully addressed the low selling price issues that led to the initial suspension.
Key points to consider:
- The lifting of the trading suspension suggests improved investor confidence and potentially increased liquidity for SCPX shares.
- Resumption of trading on a major exchange like NYSE American provides greater visibility and accessibility for both retail and institutional investors.
- The company's ability to meet the NYSE American's listing requirements demonstrates financial stability and compliance with regulatory standards.
However, investors should exercise caution:
- The previous trading suspension may have been indicative of underlying financial or operational challenges that require further scrutiny.
- The biotech CDMO sector is highly competitive and Scorpius will need to demonstrate strong performance to maintain its listing status and attract investor interest.
- Future financial reports and operational updates will be important in assessing the company's long-term viability and growth prospects.
Overall, while the resumption of trading is a positive sign, investors should conduct thorough due diligence on Scorpius Holdings' fundamentals and market position before making investment decisions.
The reinstatement of Scorpius Holdings on the NYSE American exchange is a noteworthy event in the context of the broader CDMO market. This development could have several implications for the company's competitive positioning:
- Market Perception: The lifting of the trading suspension may enhance Scorpius' reputation among potential clients in the pharmaceutical and biotech industries, potentially leading to new business opportunities.
- Investor Accessibility: Resumed trading on a major exchange increases the company's visibility to a wider range of investors, which could improve its ability to raise capital for future expansion or R&D initiatives.
- Industry Trends: The CDMO market is experiencing rapid growth, driven by increasing outsourcing of drug development and manufacturing. Scorpius' focus on biologics and cell therapies aligns with high-growth segments of the industry.
However, it's important to consider:
- The competitive landscape in the CDMO space is intensifying, with both established players and new entrants vying for market share.
- Scorpius will need to demonstrate strong operational performance and client acquisition to capitalize on its improved market status.
- The company's ability to leverage its state-of-the-art facilities in San Antonio and deliver on its promise of transparent collaboration will be important for long-term success.
Investors and industry observers should closely monitor Scorpius' performance metrics, client announcements and financial results in the coming quarters to gauge its trajectory in the dynamic CDMO market.
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the staff of NYSE Regulation has withdrawn its delisting determination and will be lifting the trading suspension of the Company's common stock on the NYSE American. The NYSE Regulation staff determined that the Company's common stock was now trading above the threshold of low selling price issues as further defined by Section 1003(f)(v) of the NYSE American Company Guide. Scorpius’ common stock is expected to resume trading on the NYSE American on Friday, August 2, 2024, under the symbol "SCPX" and Cusip “42237K 508.”
Scorpius Holdings, Inc.
Scorpius Holdings, Inc. is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. Scorpius offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, Texas. With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing. For more information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions, and include statements regarding the Common Stock resuming trading on the NYSE American on Friday, August 2, 2024, under the symbol "SCPX." Important factors that could cause actual results to differ materially from current expectations include, among others, the ability of the Company to resume trading on Friday, August 2, 2024 and have its Common Stock remain listed and recommence trading on the NYSE American; the Company’s financing needs; its cash balance being sufficient to sustain operations and its ability to raise capital when needed; the Company’s ability to leverage fixed costs and achieve long-term profitability; the Company’s ability to obtain regulatory approvals or to comply with ongoing regulatory requirements; regulatory limitations relating to the Company’s ability to successfully promote its services and compete as a pure- play CDMO; and other factors described in the Company’s annual report on Form 10-K for the year ended December 31, 2023, subsequent quarterly reports on Form 10-Qs and any other filings the Company makes with the SEC. The information in this presentation is provided only as of the date presented, and the Company undertakes no obligation to update any forward-looking statements contained in this presentation on account of new information, future events, or otherwise, except as required by law.
Media and Investor Relations Contact
David Waldman
+1 919 289 4017
ir@scorpiusbiologics.com
FAQ
When will Scorpius Holdings (SCPX) resume trading on the NYSE American?
Why was the trading suspension of Scorpius Holdings (SCPX) lifted?
What is the main business of Scorpius Holdings (SCPX)?
Where are Scorpius Holdings' (SCPX) facilities located?
